In the most recent update of this trial, grade 3/4 adverse events (AEs) included: neutropenia (83%), leukopenia (56%), elevated alanine aminotransferase (ALT) (13%), elevated aspartate aminotransferase (AST) (13%), and thrombocytopenia (10%), and no ILD was observed [34]. This evidence concerns the gene GPT and Thrombocytopenia.